24 patients with various hematologic malignancies recieved PBSCT/BMT from their HLA matched or unrelated donors and haploidentical siblings in April-December 2007. 24例不同血液病患者接受HLA全相合同胞、非血缘供者或单倍体相合同胞造血干细胞移植。 更多例句>> 2) HLA non-identical HLA不全相合 1. ...
HLA-matched allo-transplantation is beneficial for younger patients with AMLAllogeneic stem-cell transplantation (allo-SCT) after myeloablative therapy is commonly used in patients with acute myeloid leukemia (AML) who are in first complete remission (CR1). Whether allo-SCT results in better survival...
HLA-matched sibling donors (MSDs) are preferred for hematopoietic cell transplantation (HCT). However, the use of alternative donors, especially haploidentical, is increasing, as is our understanding of the impact of HLA factors such as B-leader and DRB1-matching on its outcomes. Yet, data ...
HLA-matched platelets should always be irradiated to prevent TA-GVHD. Ordering HLA-matched platelets may require a marked time delay of days to weeks or may not even be possible. Consult your blood bank physician and/or hematologist for recommendations in managing bleeding patients with alloimmune ...
Severe combined immunodeficiency (SCID) is fatal in infancy unless corrected with allogeneic bone marrow transplants (BMT), preferably from a family-related genotypically HLA-identical donor (RID) or phenotypically HLA-matched family donor (PMD). For the majority of SCID patients, such donors are ...
This study included patients (age < 20 years) who had received an HLA-matched sibling BMT for β-thalassemia major between 1995 and 2001 and received myeloablative conditioning (busulfan + cyclophosphamide). During this period, 233 patients met the selection criteria. Thirty-one transplantation ...
Author Correction: Simulation shows that HLA-matched stem cell donors can remain unidentified in donor searches Correction to:Scientific Reportshttps://doi.org/10.1038/srep21149, published online 15 February 2016 This Article contains an error. In the original version of the Article, Figure 5 was ...
Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anemia Br J Haematol, 130 (2005), pp. 99-106 CrossrefView in ScopusGoogle Scholar 7 H. Glucksberg, R. Storb, A. Fefer, et al. Clinical manifestations of graft...
Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMTRefractory or relapsed acute myeloid leukemia (R/R-AML) has poor prognosis. Allogeneic ...
We analyzed subsequent cancers in 329 patients with aplastic anemia given HLA-matched related marrow grafts. Median follow-up: 26 (range 1–47) years. Conditioning: cyclophosphamide±antithymocyte globulin; graft-vs.-host disease (GVHD) prevention: methotrexate±cyclosporine. The long follow-up and ...